Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-10-17 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Wayrilz de Sanofi recommandé par le CHMP pour être approuvé par l’UE dans le cadre du traitement de la thrombocytopénie immunitaire
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing a positive recommendation from the CHMP (Committee for Medicinal Products for Human Use) regarding the approval of their drug 'Wayrilz' for the treatment of immune thrombocytopenia (ITP). It details the clinical study results (LUNA 3), the regulatory status, and provides contact information for press and investor relations. This is a standard corporate announcement regarding regulatory progress and product development, which falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement that does not fit into more specific categories like earnings releases or financial reports.
2025-10-17 French
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi regarding a positive regulatory opinion (CHMP) for a new drug, Wayrilz. It details clinical trial results, regulatory status, and company contact information. As it is a general corporate announcement regarding regulatory progress that does not fit into specific categories like financial reports, earnings releases, or legal proceedings, it falls under the 'Regulatory Filings' (RNS) category as the standard fallback for such corporate news.
2025-10-17 English
Communiqué de presse : Sanofi fournit une mise à jour de l’examen réglementaire du Rezurock dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi regarding a negative regulatory opinion from the European Medicines Agency (EMA) for their drug Rezurock. It details the clinical context, the company's response, and future steps. As it is a general regulatory announcement regarding product development and regulatory status that does not fit into specific categories like financial results or shareholder meetings, it falls under the 'Regulatory Filings' (RNS) category.
2025-10-17 French
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi regarding a negative regulatory opinion from the European Medicines Agency (EMA) for their drug Rezurock. It discusses clinical trial results, regulatory status, and the company's intent to seek re-examination. As this is a general regulatory announcement regarding product development and regulatory status that does not fit into specific financial reporting categories like earnings or dividends, it is classified as a Regulatory Filing (RNS).
2025-10-17 English
6-K
Foreign Filer Report
2025-10-15 English
Sanofi: Information concerning the total number of voting rights and shares - September 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document provides a periodic update on the total number of shares and voting rights for Sanofi, citing Article L. 233-8 II of the French Commercial Code. This type of disclosure is a standard regulatory requirement for French listed companies to report their capital structure and voting rights. It does not constitute a shareholder vote result (DVA), a major shareholding notification (MRQ), or a share buyback (POS), but rather a routine regulatory disclosure of share capital status. Therefore, it falls under the general regulatory filing category.
2025-10-14 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.